Table 1 Patient characteristics of the Burdenko’s Glioblastoma Progression Dataset (Burdenko) and the GlioCMV UKER progression dataset (UKER).
Variable | Burdenko (n = 59) | GlioCMV UKER (n = 20) |
|---|---|---|
Gender | ||
Female, n (%) | 28 (47.5) | 11 (55) |
Male, n (%) | 31 (52.5) | 9 (45) |
IDH Mutation Status | ||
Mutant, n (%) | 8 (13.6) | 1 (5) |
Wildtype, n (%) | 36 (61.0) | 19 (95) |
Unknown, n (%) | 15 (25.4) | 0 (0) |
MGMT Methylation Status | ||
Methylated, n (%) | 14 (23.7) | 9 (45) |
Unmethylated, n (%) | 23 (40.0) | 3(15) |
Unknown, n (%) | 22 (37.3) | 8 (40) |
Progression Classification | ||
True Progression, n (%) | 34 (57.6) | 11 (55) |
Pseudoprogression, n (%) | 25 (42.4) | 9 (45) |
Age in years, median, range | 57, (18–82) | 58.5, (45–75) |
